Operating margin moved 716 bp higher
Operating margin changed +716 basis points from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating margin changed +716 basis points from the comparable as-filed period.
Free-cash-flow proxy changed +36.5% from the comparable as-filed period.
Operating cash flow changed +23.5% from the comparable as-filed period.
Net income changed +193.3% from the comparable as-filed period.
SBC / revenue changed -467 basis points from the comparable as-filed period.
Capital expenditure changed -72.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed +604.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Revenue changed +10.4% from the comparable as-filed period.
Capex / revenue changed -113 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Stock-based compensation changed -26.8% from the comparable as-filed period.
Debt changed -12.2% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
Research & development changed -5.8% from the comparable as-filed period.
Debt changed -62.4% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Free-cash-flow proxy changed +72.9% from the comparable as-filed period.
Operating cash flow changed +61.1% from the comparable as-filed period.
Operating margin changed +799 basis points from the comparable as-filed period.
SBC / revenue changed -451 basis points from the comparable as-filed period.
Revenue changed +12.9% from the comparable as-filed period.
Operating income changed +305.3% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Cash & equivalents changed -15.9% from the comparable as-filed period.
Net income changed +175.7% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Research & development changed -11.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Capital expenditure changed +23.0% from the comparable as-filed period.
Stock-based compensation changed -21.3% from the comparable as-filed period.
Capex / revenue changed +27 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.